equinox glp 1 protocol GLP-1 medications that suppress appetite are allowing people to better manage diabetes and obesity. As weight-loss drug popularity soars, more benefits and risks of the drugs are emerging “People Will Pay Anything for

10.1016/j.metabol.2012.06.010 272

1, citing soaring costs that are overwhelming insurers and employers

Our body was created to store excess calories as fat, as a source of energy for a future rainy day

Available from: com/intelligence/pages/antiobesity-drug-market.html 8 Erman, M., 2023

From a clinical point of view, functionally relevant, dopa-refractory clinical outcome measures are needed in disease-modifying PD clinical trials, ideally combined with promising exploratory endpoints, such as digital health technologies, wet biomarkers, and imaging techniques, for patient stratification, confirmation of target engagement, and tracking of disease progression